Products

Crizotinib (CAS 877399-52-5) is an orally bioavailable, ATP‑competitive inhibitor of the receptor tyrosine kinases c‑Met (hepatocyte growth factor receptor) and anaplastic lymphoma kinase (ALK). The molecule features a pyridin‑2‑amine core with a piperidin‑4‑yl‑pyrazole substituent and a dichlorofluorophenyl‑ethoxy side chain.

Ruxolitinib (CAS 941678-49-5) is a potent, orally bioavailable, and selective dual inhibitor of Janus kinases 1 and 2 (JAK1/JAK2). The molecule features a pyrrolo[2,3‑d]pyrimidine core with a cyclopentyl and pyrazole‑containing side chain. This unique structural architecture enables Ruxolitinib to inhibit JAK1 with an IC₅₀ of 3.3 nM and JAK2 with an IC₅₀ of 2.8 nM in cell‑free assays.

Lenalidomide (CAS 191732-72-6) is a potent immunomodulatory drug and second‑generation thalidomide analog. The molecule features an isoindolinone core with an amino group at the 4‑position and a 2,6‑dioxopiperidin‑3‑yl substituent at the 2‑position.

Pomalidomide (CAS 19171-19-8) is a potent immunomodulatory agent and third‑generation thalidomide analog. The molecule features an isoindoline‑1,3‑dione core with an amino group at the 4‑position and a 2,6‑dioxopiperidin‑3‑yl substituent at the 2‑position. This unique structural architecture enables Pomalidomide to bind cereblon (CRBN), a component of the cullin‑RING E3 ubiquitin ligase complex, with high affinity.

Erlotinib Hydrochloride (CAS 183319-69-9) is a first‑generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor belonging to the quinazolinamine class. The molecule features a quinazoline core with bis(2‑methoxyethoxy) substituents at the 6,7‑positions and an ethynylanilino group at the 4‑position, with the hydrochloride salt formed at the quinazoline nitrogen.

Sunitinib Malate (CAS 341031-54-7) is the orally bioavailable L‑malate salt of an indolinone‑based multi‑targeted receptor tyrosine kinase (RTK) inhibitor. The molecule features a pyrrole‑carboxamide core linked to an indolinone moiety via an unsaturated carbon bridge, with the L‑malate counterion enhancing the compound‘s physicochemical properties.